



This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Endocrine/m	etabolic disease			
Diabetes	Unknown	Cell culture and mouse studies suggest a diarylureabased compound could help regenerate β cell mass and treat type 1 diabetes. In an islet proliferation assay, the compound increased proliferation of primary rat and human islets compared with vehicle. In a mouse model for β cell ablation, the compound increased β cell mass and decreased blood glucose levels compared with vehicle. Next steps include efficacy studies in the nonobese diabetic mice. \$\mathref{SciBX}\$ 6(6); doi:10.1038/scibx.2013.139 Published online Feb. 14, 2013	Patent application filed; unlicensed	Shen, W. et al. J. Am. Chem. Soc.; published online Jan. 19, 2013; doi:10.1021/ja309304m Contact: Peter G. Schultz, The Scripps Research Institute, La Jolla, Calif. e-mail: schultz@scripps.edu Contact: Richard Glynne, The Genomics Institute of the Novartis Research Foundation, San Diego, Calif. e-mail: rglynne@gnf.org